Clinical Research Directory
Browse clinical research sites, groups, and studies.
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Sponsor: Suzhou Alphamab Co., Ltd.
Summary
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Official title: An Open, Randomized, Active-comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of Different Doses of KN060 for the Prevention of Venous Thromboembolism in Patients Undergoing Unilateral Total Knee Arthroplasty.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
241
Start Date
2023-12-20
Completion Date
2026-04-15
Last Updated
2025-09-17
Healthy Volunteers
No
Conditions
Interventions
Enoxaparin
40 mg enoxaparin administered as subcutaneous injection once daily
KN060 Low
Single dose of KN060 administered as intravenous infusion
KN060 Middle
Single dose of KN060 administered as intravenous infusion
KN060 Hight
Single dose of KN060 administered as intravenous infusion
Locations (1)
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China